![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Approves Mylan’s Herceptin Biosimilar
FDA Approves Mylan’s Herceptin Biosimilar
![Purple_Approved_Stamp.gif](https://www.fdanews.com/ext/resources/test/Drug-Images4/Purple_Approved_Stamp.gif?t=1576639773&width=430)
December 5, 2017
The FDA approved Mylan’s Ogivri (trastuzumab-dkst), the first U.S. biosimilar for Genentech’s Herceptin, for the treatment of breast or metastatic stomach cancer with HER2-positive tumors.
Ogivri is the second FDA-approved cancer biosimilar — the first being Amgen’s Avastin biosimilar, Mvasi (bevacizumab-awwb), approved in September.
Ogivri was not approved as an interchangeable product. Like Herceptin, the biosimilar carries a Boxed Warning about increased risks of heart disease, infusion reactions, lung damage and pregnancy harms.
Upcoming Events
-
21Oct